Address

Novartis Venture Fund
100 Technology Square
Cambridge, MA 02139
United States

Open map

Novartis Venture Fund
c/o Novartis International AG
Postfach CH-4002
Basel
Switzerland

Open map

KANDO id: 42466

Corporate information

Also known as
Novartis Venture Fund
Registration country

Funding rounds

Investment preferences

Investment criteria
We are stage agnostic (seed to commercial companies) and invest in multiple therapeutic areas where there is clear unmet medical need. Our first step in the process is to review non-confidential information about the company, team, technology / data, financial and exit plan. The further evaluation of business proposals is then based on confidential presentations by the management team that starts the full due diligence process.

Investments by the Novartis Venture Fund are made as equity participation typically as the lead or co-lead investor in a syndicate with a board seat.
Investment focus themes
Top investment portfolio themes
healthcare (1)  

Actual initial investment stage
N/A (2)

Investment activity status
Active investor

Selected investments

Displaying 51 - 75 of 83
Profile Country Funding
Bicycle Therapeutics Ltd A biotechnology company developing a novel technology platform for the creation of a new generation of biotherapeutics. N/A
Autonomic Technologies Inc N/A
Atlas Genetics Ltd N/A
Forma Therapeutics Inc N/A
AMP Therapeutics GmbH N/A
Alios BioPharma Inc N/A
Advanced Animal Diagnostics Inc Develops rapid diagnostic tools to detect and manage disease states, reproductive, nutritional and overall health status of livestock animals. N/A
Adenosine Therapeutics LLC N/A
Aileron Therapeutics Inc Developing a breakthrough proprietary peptide technology platform N/A
Akebia Therapeutics Inc N/A
Tokai Pharmaceuticals Inc Developer of prostate cancer drugs N/A
Ablation Frontiers Inc Medical device company that has developed and marketed cardiac ablation devices. N/A
Intellikine N/A Initial investment
Genedata AG N/A
Polyphor Ltd N/A
PharmAbcine Inc Develops fully human therapeutic monoclonal antibody (mAb) N/A
Paratek Pharmaceuticals Inc N/A
Oxagen Ltd N/A
Opsona Therapeutics Ltd Innate immune drug development company N/A
Okairos AG N/A
NovImmune SA N/A
Neomics Co Ltd N/A
Nabriva Therapeutics AG N/A
MyoPowers Medical Technologies SA N/A
Merus Biopharmaceuticals BV Dutch antibody company focused on the use of two proprietary technologies to build a pipeline of innovative human therapeutic antibodies: the Oligoclo N/A

Current team

Past employees

Selected Products / Customers

Financials